Market capitalization | $19.88b |
Enterprise Value | $31.19b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 60.21 |
EV/Sales (TTM) EV/Sales | 2.08 |
P/S ratio (TTM) P/S ratio | 1.33 |
P/B ratio (TTM) P/B ratio | 2.60 |
Dividend yield | 2.98% |
Last dividend (FY23) | $1.16 |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
16 Analysts have issued a Baxter International forecast:
16 Analysts have issued a Baxter International forecast:
Jun '24 |
+/-
%
|
||
Revenue | 14,997 14,997 |
0%
0%
|
|
Gross Profit | 5,556 5,556 |
2%
2%
|
|
EBITDA | 2,772 2,772 |
1%
1%
|
EBIT (Operating Income) EBIT | 1,514 1,514 |
4%
4%
|
Net Profit | -406 -406 |
86%
86%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Baxter International, Inc. provides portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies; premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software and services. It operates through the following segment: Americas, Europe, Middle East & Africa and Asia-Pacific. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.
Head office | United States |
CEO | Joe Almeida |
Employees | 60,000 |
Founded | 1931 |
Website | www.baxter.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.